The acquisition expands the medical laser platform into high-growth, high-margin markets, establishing leadership in ophthalmology and complementing existing strengths. The €300 million deal is expected to be accretive to margins and EPS, with closing targeted for Q4 2026.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.